J. Schiller, Comparison of Four Chemotherapy Regimens for Advanced Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.346, issue.2, pp.92-98, 2002.
DOI : 10.1056/NEJMoa011954

G. Scagliotti, P. Parikh, J. Von-pawel, B. Biesma, J. Vansteenkiste et al., Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.26, issue.21, pp.3543-3551, 2008.
DOI : 10.1200/JCO.2007.15.0375

J. Mackey, R. Mani, M. Selner, D. Mowles, J. Young et al., Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines, Cancer Res, vol.58, pp.4349-4357, 1998.

V. Heinemann, L. Hertel, G. Grindey, and W. Plunkett, Comparison of the cellular pharmacokinetics and toxicity of 2?, 2?-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine, Cancer Res, vol.48, pp.4024-4031, 1988.

P. Huang, S. Chubb, L. Hertel, G. Grindey, and W. Plunkett, Action of 2?, 2?-difluorodeoxycytidine on DNA synthesis, Cancer Res, vol.51, pp.6110-6117, 1991.

V. Heinemann, Y. Xu, S. Chubb, A. Sen, L. Hertel et al., Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2?, Mol Pharmacol, vol.38, pp.2-567, 1990.

W. Plunkett, P. Huang, Y. Xu, V. Heinemann, R. Grunewald et al., Gemcitabine: metabolism, mechanisms of action, and self-potentiation, Semin Oncol, vol.22, issue.4, pp.3-10, 1995.

H. Kirch, J. Schroder, H. Hoppe, H. Esche, S. Seeber et al., Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro, Exp Hematol, vol.26, pp.421-425, 1998.

J. Gilbert, Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional Genomics, Clinical Cancer Research, vol.12, issue.6, pp.1794-1803, 2006.
DOI : 10.1158/1078-0432.CCR-05-1969

F. Wachters, First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial, British Journal of Cancer, vol.89, issue.7, pp.1192-1199, 2003.
DOI : 10.1038/sj.bjc.6601283

D. Cockcroft and M. Gault, Prediction of Creatinine Clearance from Serum Creatinine, Nephron, vol.16, issue.1, pp.31-41, 1976.
DOI : 10.1159/000180580

K. Freeman, Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection, Journal of Chromatography B: Biomedical Sciences and Applications, vol.665, issue.1, pp.171-181, 1995.
DOI : 10.1016/0378-4347(94)00521-6

J. Abbruzzese, A phase I clinical, plasma, and cellular pharmacology study of gemcitabine., Journal of Clinical Oncology, vol.9, issue.3, pp.491-498, 1991.
DOI : 10.1200/JCO.1991.9.3.491

E. Sugiyama, Pharmacokinetics of Gemcitabine in Japanese Cancer Patients: The Impact of a Cytidine Deaminase Polymorphism, Journal of Clinical Oncology, vol.25, issue.1, pp.32-42, 2007.
DOI : 10.1200/JCO.2006.06.7405

L. Yue, Y. Saikawa, K. Ota, M. Tanaka, R. Nishimura et al., A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity, Pharmacogenetics, vol.13, issue.1, pp.29-38, 2003.
DOI : 10.1097/00008571-200301000-00005

A. Fukunaga, S. Marsh, D. Murry, T. Hurley, and H. Mcleod, Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway, The Pharmacogenomics Journal, vol.4, issue.5, pp.307-314, 2004.
DOI : 10.1038/sj.tpj.6500259

L. Betts, S. Xiang, S. Short, R. Wolfenden, and C. Carter, Cytidine Deaminase. The 2??3 ?? Crystal Structure of an Enzyme: Transition-state Analog Complex, Journal of Molecular Biology, vol.235, issue.2, pp.635-656, 1994.
DOI : 10.1006/jmbi.1994.1018

S. Demontis, M. Terao, M. Brivio, S. Zanotta, M. Bruschi et al., Isolation and characterization of the gene coding for human cytidine deaminase, Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, vol.1443, issue.3, pp.323-333, 1998.
DOI : 10.1016/S0167-4781(98)00235-8

G. Perez-manga, Gemcitabine in Combination With Doxorubicin in Advanced Breast Cancer: Final Results of a Phase II Pharmacokinetic Trial, Journal of Clinical Oncology, vol.18, issue.13, pp.2545-2552, 2002.
DOI : 10.1200/JCO.2000.18.13.2545

S. Fogli, R. Danesi, A. Gennari, S. Donati, P. Conte et al., Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer, Annals of Oncology, vol.13, issue.6, pp.919-927, 2002.
DOI : 10.1093/annonc/mdf164

P. Conte, Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*, Breast Cancer Research and Treatment, vol.17, issue.4, pp.171-179, 2001.
DOI : 10.1023/A:1011945623464

D. Bathla, R. Gerbing, T. Alonzo, H. Conner, J. Ross et al., Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acue myeloid leukemia, Br J Haematol, vol.144, pp.388-394, 2008.

C. Tibaldi, E. Giovannetti, E. Vasile, V. Mey, A. Laan et al., Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients, Clinical Cancer Research, vol.14, issue.6, pp.1797-1803, 2008.
DOI : 10.1158/1078-0432.CCR-07-1364